Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for F. Hoffmann-La Roche AG
15.20
-0.19 (-1.23%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.17 - 15.47
52 week 9.16 - 17.55
Open 15.38
Vol / Avg. 0.00/891,325.00
Mkt cap 2.05B
P/E     -
Div/yield     -
EPS -1.01
Shares 136.26M
Beta 1.71
Inst. own 103%
Aug 3, 2016
Q2 2016 Nektar Therapeutics Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 23, 2016
Nektar Therapeutics Annual Shareholders Meeting
Jun 22, 2016
Nektar Therapeutics at ROTH Healthcare Day
Jun 15, 2016
Nektar Therapeutics Annual Shareholders Meeting (Estimated)
Jun 8, 2016
Nektar Therapeutics at Jefferies Healthcare Conference
May 5, 2016
Nektar Therapeutics at Deutsche Bank Health Care Conference
May 3, 2016
Q1 2016 Nektar Therapeutics Earnings Call
May 3, 2016
Q1 2016 Nektar Therapeutics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -33.11% -35.17%
Operating margin -16.11% -18.83%
EBITD margin - -7.16%
Return on average assets -15.74% -17.20%
Return on average equity -2541.64% -379.68%
Employees 435 -
CDP Score - -

Address

455 Mission Bay Blvd S
SAN FRANCISCO, CA 94158-2158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Gilbert M. Labrucherie J.D. Chief Financial Officer, Senior Vice President
Age: 43
Bio & Compensation  - Reuters
John L. Nicholson Chief Operating Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Senior Vice President - Drug Development & Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 61
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 56
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 63
Bio & Compensation  - Reuters